J Bone Metab.  2018 Feb;25(1):23-33. 10.11005/jbm.2018.25.1.23.

α-Tocopheryl Succinate Inhibits Osteolytic Bone Metastasis of Breast Cancer by Suppressing Migration of Cancer Cells and Receptor Activator of Nuclear Factor-κB Ligand Expression of Osteoblasts

• Kim B
• Kim HH
• Lee ZH

• KMID: 2406236
• DOI: http://doi.org/10.11005/jbm.2018.25.1.23

Abstract

BACKGROUND
Breast cancer is one of the most common cancers affecting women and has a high incidence of bone metastasis, causing osteolytic lesions. The elevated expression of receptor activator of nuclear factor-κB ligand (RANKL) in cancer activates osteoclasts, leading to bone destruction. We previously reported that α-tocopheryl succinate (αTP-suc) inhibited interleukin-1-induced RANKL expression in osteoblasts. Here, we examined the effect of αTP-suc on osteolytic bone metastasis in breast cancer.
METHODS
To examine the effect of αTP-suc on the metastatic capacity of breast cancer, MDA-MB-231-FL cells were injected into the left cardiac ventricle of BALB/c nude mice along with intraperitoneal injection of αTP-suc. The mice were then analyzed by bioluminescence imaging. To investigate the effect of αTP-suc on osteolysis, 4T1 cells were directly injected into the femur of BALB/c mice along with intraperitoneal injection of αTP-suc. Microcomputed tomography analysis and histomorphometric analysis of the femora were performed.
RESULTS
αTP-suc inhibited cell migration and cell growth of 4T1 cells. In line with these results, bone metastasis of MDA-MB-231-FL cells was reduced in mice injected with αTP-suc. In addition, αTP-suc decreased osteoclastogenesis by inhibiting 4T1-induced RANKL expression in osteoblasts. Consistent with these results, 4T1-induced bone destruction was ameliorated by αTP-suc, with in vivo analysis showing reduced tumor burden and osteoclast numbers.
CONCLUSIONS
Our findings suggest that αTP-suc may be efficiently utilized to prevent and treat osteolytic bone metastasis of breast cancer with dual effects.

Keyword

Alpha-tocopheryl succinate; Breast neoplasms; Osteolysis

MeSH Terms

Animals
Breast Neoplasms*
Breast*
Cell Movement
Female
Femur
Heart Ventricles
Humans
Incidence
Injections, Intraperitoneal
Mice
Mice, Nude
Neoplasm Metastasis*
Osteoblasts*
Osteoclasts
Osteolysis
Succinic Acid*
Tumor Burden
X-Ray Microtomography
Succinic Acid

Figure

• 

  Fig. 1 Effect of α-tocopheryl succinate (αTP-suc) on the cell migration and cell viability of 4T1 cells. (A, B) Cell migration of serum-starved 4T1 cells in response to 10% fetal bovine serum in the presence of dimethyl sulfoxide (DMSO) or different concentrations of αTP-suc (1–10 µM) was assessed in transwell chambers for 12 hr. (A) Representative images of hematoxylin and eosin staining, ×100 magnification; and scale bar, 200 µm. (B) The number of migrated 4T1 cells per field (n=6 per each well). (C) The 4T1 cells were cultured with DMSO or different concentrations of αTP-suc (1–10 µM) for 2 days and then cell viability was measured. The results shown are representative of three independent experiments (n=3), and the values are expressed as mean±standard deviation. ***P<0.001 vs. vehicle treatment by unpaired Student's t-test. FBS, fetal bovine serum.

• 

  Fig. 2 Effect of α-tocopheryl succinate (αTP-suc) on metastasis by intracardiac injection of MDA-MB-231-FL (MDA-FL) cells. MDA-MB-231-FL cells or phosphate-buffered saline was injected into the left cardiac ventricle and metastasis of cancer was analyzed on day 7 after injection of cancer. Starting 1 day before cancer injection, αTP-suc (0.1 mg/head) or dimethyl sulfoxide (DMSO) was injected intraperitoneally every 2 days (n =5 each). (A) Scheme of the intracardiac injection mouse model. (B) Representative bioluminescence images. (C) Bioluminescence imaging analysis of tumor burden in the whole body. The values are expressed as mean±standard error of the mean. †P<0.05 vs. DMSO-injected mice with injection of MDA-MB-231-FL cells by one-way repeated-measures analysis of variance followed by Dunnett's test. i.p., intraperitoneally.

• 

  Fig. 3 Effect of α-tocopheryl succinate (αTP-suc) on osteoclast differentiation in triple co-culture and on 4T1 cell-conditioned medium (4T1-CM)-induced receptor activator of nuclear factor-κB ligand (RANKL) expression in osteoblasts (OBs). (A, B) Primary bone marrow cells and OBs were co-cultured with or without 4T1 cells in the presence of dimethyl sulfoxide (DMSO) or αTP-suc (10 µM) for 8 days. (A) Representative images of tartrate-resistant acid phosphatase staining, ×100 magnification; and scale bar, 200 µm. (B) The number of osteoclasts. ***P<0.001 vs. DMSO-treated control by unpaired Student's t-test. (C, D) OBs were cultured with or without 4T1-CM (30%) in the presence of DMSO or different concentrations of αTP-suc (1–10 µM) for 24 hr. (C) Levels of RANKL messenger RNA (mRNA) (left panel) and osteoprotegerin (OPG) mRNA (right panel) were measured by real-time polymerase chain reaction analysis. (D) Levels of RANKL protein (left panel) and OPG protein (right panel) in the culture media were measured by enzyme-linked immunosorbent assay. The results shown are representative of three independent experiments (n=3), and the values are expressed as mean±standard deviation. ***P<0.001 vs. untreated control and †††P<0.001; ††P<0.01; †P<0.05 vs. DMSO-treated cells in response to 4T1-CM by unpaired Student's t-test. BMC, bone marrow cell.

• 

  Fig. 4 Effect of α-tocopheryl succinate (αTP-suc) on the bone destruction by 4T1 cells in the mouse model of intrafemoral injection. The 4T1 cells were directly injected into the left femur. Starting 1 day before cancer injection, αTP-suc (0.1 mg/head) or dimethyl sulfoxide (DMSO) was injected intraperitoneally every 2 days (n=5 each). After 7 days of 4T1 injection, left femora were collected and analyzed by microcomputed tomography (micro-CT) scanning. (A) Scheme of the intrafemoral injection mouse model. (B) Representative reconstructed images by micro-CT (scale bar, 0.7 mm). (C) Quantification of trabecular bone parameters: bone volume per total volume (BV/TV, left upper panel), trabecular thickness (Tb.Th, right upper panel), trabecular number (Tb.N, left bottom panel), and trabecular separation (Tb.Sp, right bottom panel). The values are expressed as mean±standard error of the mean. ***P<0.001; *P<0.05 vs. phosphate-buffered saline-injected mice and †P<0.05 vs. DMSO-injected mice with injection of 4T1 cells by one-way repeated-measures analysis of variance followed by Dunnett's test. n.s., not significant; i.p., intraperitoneally.

• 

  Fig. 5 Effect of α-tocopheryl succinate on tumor burden and osteoclast number by 4T1 cells. Histological analysis of bone metastasis from the experimental groups in Figure 4 (n=5). (A) Representative images of hematoxylin and eosin (H & E)-stained femur sections, ×100 magnification; and scale bar, 500 µm. (B) Histomorphometric quantification of tumor burden from H & E sections. (C) Representative images of tartrate-resistant acid phosphatase (TRAP)-stained femur sections, ×400 magnification; and scale bar, 200 µm. (D) Histomorphometric quantification of osteoclast numbers from TRAP-stained sections. †P<0.05 vs. dimethyl sulfoxide (DMSO)-injected mice with injection of 4T1 cells by one-way repeated-measures analysis of variance followed by Dunnett's test. T, tumor; BM, bone marrow; B, bone; αTP-suc, α-tocopheryl succinate.

Reference

1. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004; 350:1655–1664.

2. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001; 27:165–176.

3. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2:584–593.

4. Chen YC, Sosnoski DM, Mastro AM. Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res. 2010; 12:215.

5. Wang N, Docherty FE, Brown HK, et al. Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models. J Bone Miner Res. 2014; 29:2688–2696.

6. Croucher PI, McDonald MM, Martin TJ. Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer. 2016; 16:373–386.

7. Ju J, Picinich SC, Yang Z, et al. Cancer-preventive activities of tocopherols and tocotrienols. Carcinogenesis. 2010; 31:533–542.

8. Husain K, Francois RA, Yamauchi T, et al. Vitamin E delta-to-cotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-kappaB activation in pancreatic cancer. Mol Cancer Ther. 2011; 10:2363–2372.

9. Gysin R, Azzi A, Visarius T. Gamma-tocopherol inhibits human cancer cell cycle progression and cell proliferation by down-regulation of cyclins. FASEB J. 2002; 16:1952–1954.

10. Alqahtani S, Kaddoumi A. Vitamin E transporters in cancer therapy. AAPS J. 2015; 17:313–322.

11. Kim HN, Lee JH, Jin WJ, et al. alpha-Tocopheryl succinate inhibits osteoclast formation by suppressing receptor activator of nuclear factor-kappaB ligand (RANKL) expression and bone resorption. J Bone Metab. 2012; 19:111–120.

12. Savitskaya MA, Onischenko GE. alpha-Tocopheryl succinate affects malignant cell viability, proliferation, and differentiation. Biochemistry (Mosc). 2016; 81:806–818.

13. Lee JH, Kim HN, Yang D, et al. Trolox prevents osteoclastogenesis by suppressing RANKL expression and signaling. J Biol Chem. 2009; 284:13725–13734.

14. Lee JH, Kim HN, Kim KO, et al. CXCL10 promotes osteolytic bone metastasis by enhancing cancer outgrowth and osteoclastogenesis. Cancer Res. 2012; 72:3175–3186.

15. Jin WJ, Kim B, Kim D, et al. NF-kappaB signaling regulates cell-autonomous regulation of CXCL10 in breast cancer 4T1 cells. Exp Mol Med. 2017; 49:e295.

16. Wang D, Chuang HC, Weng SC, et al. alpha-Tocopheryl succinate as a scaffold to develop potent inhibitors of breast cancer cell adhesion. J Med Chem. 2009; 52:5642–5648.

17. Davis-Yadley AH, Malafa MP. Vitamins in pancreatic cancer: a review of underlying mechanisms and future applications. Adv Nutr. 2015; 6:774–802.

18. Doldo E, Costanza G, Agostinelli S, et al. Vitamin A, cancer treatment and prevention: the new role of cellular retinol binding proteins. Biomed Res Int. 2015; 2015:624627.

19. Fritz H, Flower G, Weeks L, et al. Intravenous vitamin C and cancer: A systematic review. Integr Cancer Ther. 2014; 13:280–300.

20. Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health. 2006; 96:252–261.

21. Lamson DW, Plaza SM. The anticancer effects of vitamin K. Altern Med Rev. 2003; 8:303–318.

22. Frank J. Beyond vitamin E supplementation: an alternative strategy to improve vitamin E status. J Plant Physiol. 2005; 162:834–843.

23. Azzi A, Ricciarelli R, Zingg JM. Non-antioxidant molecular functions of alpha-tocopherol (vitamin E). FEBS Lett. 2002; 519:8–10.

24. Diplock AT. Safety of antioxidant vitamins and beta-carotene. Am J Clin Nutr. 1995; 62:1510s–1516s.

25. Müller L, Theile K, Böhm V. In vitro antioxidant activity of tocopherols and tocotrienols and comparison of vitamin E concentration and lipophilic antioxidant capacity in human plasma. Mol Nutr Food Res. 2010; 54:731–742.

26. Prasad KN, Kumar B, Yan XD, et al. Alpha-tocopheryl succinate, the most effective form of vitamin E for adjuvant cancer treatment: a review. J Am Coll Nutr. 2003; 22:108–117.

27. Futakuchi M, Fukamachi K, Suzui M. Heterogeneity of tumor cells in the bone microenvironment: mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer. Adv Drug Deliv Rev. 2016; 99:206–211.

28. Clezardin P, Teti A. Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis. 2007; 24:599–608.

29. Hauschka PV, Chen TL, Mavrakos AE. Polypeptide growth factors in bone matrix. Ciba Found Symp. 1988; 136:207–225.

30. Monteiro AC, Leal AC, Gonçalves-Silva T, et al. T cells induce pre-metastatic osteolytic disease and help bone metastases establishment in a mouse model of metastatic breast cancer. PLoS One. 2013; 8:e68171.

31. Tan W, Zhang W, Strasner A, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 2011; 470:548–553.

32. Chechlinska M, Kowalewska M, Nowak R. Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat Rev Cancer. 2010; 10:2–3.

33. Okazaki R, Watanabe R, Inoue D. Osteoporosis associated with chronic obstructive pulmonary disease. J Bone Metab. 2016; 23:111–120.

34. Ha H, Lee JH, Kim HN, et al. alpha-Tocotrienol inhibits osteoclastic bone resorption by suppressing RANKL expression and signaling and bone resorbing activity. Biochem Biophys Res Commun. 2011; 406:546–551.

35. Simmons JK, Hildreth BE 3rd, Supsavhad W, et al. Animal models of bone metastasis. Vet Pathol. 2015; 52:827–841.